CA125与HE4联合检测在卵巢肿瘤疾病中的应用价值

目的通过检测女性血清肿瘤标记物CA125（Carbohydrate antigen 125）、HEA（human epididymis gene product4），探讨其在卵巢肿瘤疾病应用中的诊断价值，为临床提供诊断依据。方法应用免疫电化学发光法检测血清CAl52和HE4，选取144例临床卵巢肿瘤患者，51例女性其他恶性肿瘤疾病和62例女性健康体检为对照组。结果144例卵巢肿瘤患者的CA125、HFA含量明显高于对照恶性肿瘤疾病患者和健康体检女性对照组（P〈0．05）；38例卵巢恶性肿瘤患者CA125、HE4高于女性其他恶性肿瘤疾病（P〈0．01）；在女性卵巢疾病患者中CA125、HE4联合检测的阳性率较单独检测CA125高（P〈0．05）。结论联合检测血清CA125、HEA对卵巢肿瘤的良恶性肿瘤的诊断和鉴别诊断具有较高的应用价值，且可以提高卵巢恶性肿瘤的早期诊断。

Application value of CA125 and HFA combining diction in ovarian tumor disease

Objective To study the value of combine detection of multiple serum tumor markers CA125 and HE4 in diagnosis of ovarian tumors patients. Methods The serum contents of CA125,HE4 in 144 patients with ovary tumors, 51 patients with other cancers and 62 healthy women were measured by automatic chemil assay. Results The contents of CA125, HE4 in 144 ovarian tumors group were significantly higher than those in benign other cancers and healthy women groups （P 〈 0.05） ; The contents of CA125 in 38 ovarian cancers were significantly higher than those in other ovarian tumors; In women ovarian cancer, the positive rates of combined detection of CA125, HE4 were higher than those of CA125 monomial detection （P 〈 0.05）. Conclusion The detection of serum CA125, HFA in assistance diagnosis has a high application value and differential diagnosis of benign or malignant ovarian tumor, and can improve the diagnosis level of early malignant ovariantumor.